VJHemOnc is committed to improving our service to you

COSTEM 2019 | Optimal GVHD prophylaxis in T-cell repleted haploidentical transplantation

VJHemOnc is committed to improving our service to you

Christopher Kanakry

Christopher Kanakry, MD, Center for Cancer Research, National Cancer Institute, Bethesda, MD, talks on the optimal graft versus host disease (GVHD) prophylaxis in T-cell repleted haploidentical transplantation at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter